The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+
Business News›Industry›Healthcare/Biotech›Healthcare›View: Covid should set the stage for India’s drive against more common and fatal diseases

View: Covid should set the stage for India’s drive against more common and fatal diseases

View: Covid should set the stage for India’s drive against more common and fatal diseases
View: Covid should set the stage for India’s drive against more common and fatal diseases
India’s response to Covid-19 will stand out as a singular and exceptional feat achieved by its public health apparatus at a time of a global health crisis — but one that didn’t much change the ground reality of the country’s public healthcare.

Synopsis

​​The emergence of multi-drug-resistant (MDR) TB strain is especially concerning, as it is resistant to the two most effective anti-TB drugs available: isoniazid and rifampicin.

Infectious diseases like diarrhoea, pneumonia and influenza are not new to India. For a country considered the ‘tuberculosis (TB) capital’ of the world, an unprecedented response to Covid-19 seems commendable and preposterous at the same time. Its response to control the pandemic with one of the severest lockdown measures otherwise has a very slack record of responding to more fatal infectious diseases. To be sure, Covid-19 compelled India to
BY
ET Bureau
5 mins read
Share This Article
  • GIFT ARTICLE
  • FONT SIZE
    AbcSmall
    AbcMedium
    AbcLarge
  • SAVE
  • COMMENT

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads
  • Comment & Engage with ET Prime community
  • Exclusive invites to Virtual Events with Industry Leaders
  • A trusted team of Journalists & Analysts who can best filter signal from noise
The Economic Times
BrowseCompanies: